Molecular Cancer · 2010 · 35 citations · 12 references
Life SciencesGeneticsOncologyCancer GeneticsGene ExpressionMolecular OncologyCancer EpigeneticsEpigenetic Alterations In CancerEpigenetic Regulation In CancerMalignant NeoplasmsTumor Suppressor Gene InactivationTumor Suppressor GenesAberrant Dna MethylationChromosome 17P LossPromoter HypermethylationTumor Suppressor Gene AlterationsTumor Suppressor Gene HypermethylationTumor Suppressor Gene LossTumor Suppressor Gene MethylationTumor Suppressor Loss
A hallmark of several human cancers is loss of heterozygosity (LOH) of chromosome 17p13. The same chromosomal region is also frequently hypermethylated in cancer. Although loss of 17p13 has been often associated with p53 genetic alteration or Hypermethylated in Cancer 1 (HIC1) gene hypermethylation, other tumor suppressor genes (TSGs) located in this region have critical roles in tumorigenesis. A novel TSG mapping on human chromosome 17p13.2 is KCTD11REN (KCTD11). We have recently demonstrated that KCTD11 expression is frequently lost in human medulloblastoma (MB), in part by LOH and in part by uncharacterized epigenetic events. Using a panel of human 177 tumor samples and their normal matching samples representing 18 different types of cancer, we show here that the down-regulation of KCTD11 protein level is a specific and a diffusely common event in tumorigenesis. Additionally, in order to characterize the regulatory regions in KCTD11 promoter, we identified a CpG island and several Sp1 binding sites on this promoter, and demonstrated that Sp1 transcription factor and DNA methylation contribute, at least in part, to regulate KCTD11 expression. Our findings identify KCTD11 as a widely down-regulated gene in human cancers, and provide a basis to understand how its expression might be deregulated in tumor cells.
12
Spl elements protect a CpG island from de novo methylation
Michael Brandeis, Dale Frank, Iiana Keshet et al. · Nature · 1994 · 703 citations
DNA methylation represses transcription in vivo
Zahava Siegfried, Sharon Eden, Monica Mendelsohn et al. · Nature Genetics · 1999 · 356 citations
The candidate oncoprotein Bcl-3 is an antagonist of pSO/NF-κB-mediated inhibition
Guido Franzoso, Vincent Bours, Sun Park et al. · Nature · 1992 · 322 citations